In breast cancer therapeutic decisions are based on the expression of estrogen (ER), progesterone
(PR), the human epidermal growth factor 2 (HER2) receptors and the proliferation marker Ki67.
However, only little is known concerning heterogeneity between the primary tumor and axillary
lymph node metastases (LNM) in the primary site. We retrospectively analyzed receptor profiles of
215 early breast cancer patients with axillary synchronous LNM. Of our cohort, 69% were therapy
naive and did not receive neoadjuvant treatment. Using immunohistochemistry, receptor status and
Ki67 were compared between core needle biopsy of the tumor (t-CNB) and axillary LNM obtained
during surgery. The discordance rates between t-CNB and axillary LNM were 12% for HER2, 6%
for ER and 20% for PR. Receptor discordance appears to already occur at the primary site. Receptor
losses might play a role concerning overtreatment concomitant with adverse drug effects, while
receptor gains might be an option for additional targeted or endocrine therapy. Hence, not only
receptor profiles of the tumor tissue but also of the synchronous axillary LNM should be considered
in the choice of treatment.
| Identifer | oai:union.ndltd.org:DRESDEN/oai:qucosa:de:qucosa:85930 |
| Date | 09 June 2023 |
| Creators | Weydandt, Laura, Nel, Ivonne, Kreklau, Anne, Horn, Lars-Christian, Aktas, Bahriye |
| Publisher | MDPI |
| Source Sets | Hochschulschriftenserver (HSSS) der SLUB Dresden |
| Language | English |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, doc-type:article, info:eu-repo/semantics/article, doc-type:Text |
| Rights | info:eu-repo/semantics/openAccess |
| Relation | 1863 |
Page generated in 0.002 seconds